How New Technologies Are Impacting the Vaccine Market

In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for use in vaccine development. Pfizer reportedly paid an upfront total of $30 million, with an additional $500 million agreed upon based on development and commercial milestones.

At the 2026 JP Morgan Healthcare conference, Novavax CEO John Jacobs said, ““This company is no longer about one product or one season. It’s about building a sustainable engine for value creation built on technology, discipline, and long-term partnerships.”

This news came during a period of regulatory uncertainty surrounding vaccines. Due to abrupt leadership changes at HHS, ACIP was forced to cancel its February meeting this year. In 2025, incoming HHS Secretary Kennedy fired the previous council and replaced the members with his own picks.

However, this hasn’t stopped vaccines from being developed and approved. In May of this year, FDA’s advisory panel voted to update COVID-19 vaccine shots to target the XFG variant. This update includes the vaccine developed in partnership with Novavax and Sanofi.

Sylvia Taylor spoke with Pharmaceutical Executivex about the current vaccine landscape and how new technologies are allowing more players to enter the space and develop new therapies. She also discussed the regulatory landscape and how vaccine developers are working around any potential issues.

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space?
Sylvia Taylor: Vaccine technologies are really having a major impact on the vaccine environment right now. Since the onset of COVID, people are disproportionately attuned to what different technology platforms are in vaccines.

Novavax is twofold: one, we have a protein-based nanoparticle technology platform that enables us to develop vaccines for a wide range of diseases, such as COVID. We also have our adjuvant matrix, which is an important part of our technology platform.

Basically, an adjuvant is an ingredient that's added to a vaccine to stimulate a potentially broader, more durable, and more potent response. It can be added to vaccines to potentially lower the cost of goods, side effect profile, and the amount of antigen a vaccine needs.

That's an incredibly important component in vaccine development, and we're finding that our adjuvant, called Matrix M, has broad applicability in a variety of disease areas. We've already proven it in COVID 19. We have an approved vaccine that's on the market, and we also proved it in malaria.

There's a malaria vaccine that utilizes matrix M, and right now we're generating data and working with partners to understand how our matrix potentially improve the immune response of existing vaccines in their portfolios, or the creation of entirely new vaccines altogether.